United States Osteoarthritis Market Research Report to 2032
ID: MRFR/Pharma/16454-HCR | 100 Pages | Author: MRFR Research Team| June 2025
Age-related conditions (OA) and the amount of older people in the US are strongly linked. As the population ages, osteoarthritis frequency rises. So it's even more important to find treatments that work for the specific problems this degenerative joint disease causes.
Relief from pain and other symptoms is growing in importance, which means that more OA medicines are needed. Pain killers, NSAIDs, and medicines that are put on the skin are all used to help people with OA deal with their pain so they can stay busy and do their daily tasks more easily.
Osteoarthritis drugs that change the disease are being used by more people. The trend now is for therapy to focus on the underlying reasons why OA happens. DMOADs try to change or slow down how the disease works. This means that they might be able to change how osteoarthritis progresses and preserve its condition.
The most common ways to treat OA are joint shots and viscosupplementation. People get shots of hyaluronic acid to keep their joints from rubbing together by making them more mobile. These methods can help with the symptoms of OA, especially in knees and other joints that bear weight.
Others popular ways to help people with OA are physical therapy and rehab classes. Active lifestyles like regular exercise, moving your joints, and muscle-strengthening activities are important for controlling OA because they keep your joints flexible and your musculoskeletal system healthy as a whole. To address OA, regenerative medicine and stem cell therapy are two methods that are gaining popularity. New techniques try to use the body's natural ways of healing to help joints heal and grow new tissue. They might work better than usual treatments.
There is a market for patient education and self-management tools. Sharing details about OA, how it gets worse, and how to alter one's way of life can assist individuals in taking charge of their condition and selecting appropriate treatments.
This market also includes the use of telemedicine and tracking from afar. Doctors can keep an eye on OA patients, give them exercise tips, and change their treatment plans using telemedicine tools that let them see patients from far away. As a result, care is easier to get and more constant.
A lot of people in the US want treatments for OA based on how much they cost and how well they work. To keep the systems that provide successful treatments for OA going, it is very important that OA medicines are as cost-effective as possible as healthcare changes.
Frequently Asked Questions (FAQ) :
The US Osteoarthritis Market is expected to be valued at 1.1 billion USD in 2024.
By 2035, the US Osteoarthritis Market is projected to reach a value of 2.9 billion USD.
The expected CAGR for the US Osteoarthritis Market during this period is 9.213%.
Hip Osteoarthritis is expected to dominate the market with a value of 1.5 billion USD by 2035.
In 2024, the market size for Spinal Osteoarthritis is expected to be 0.5 billion USD.
Key players include Teva Pharmaceutical Industries, Merck and Co., Takeda Pharmaceutical Company, and Bristol-Myers Squibb.
The market for Hip Osteoarthritis is projected to grow from 0.6 billion USD in 2024 to 1.5 billion USD by 2035.
Challenges include stringent regulatory requirements and high treatment costs affecting accessibility.
Opportunities include advancements in treatment methodologies and increasing awareness about osteoarthritis management.
Regional demand is influenced by factors like population aging and prevalence rates, particularly in urban areas.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)